Skip to Content

Lixte Biotech Holdings Inc LIXT Stock Quote

| Rating as of


Last close prices updated as of Jun 07, 2023, 3:48 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 5.56
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Blend
  • Day Range 5.55  –  6.14
  • Year Range 4.32  –  27.00
  • Market Cap 9.2655 Mil
  • Volume / Avg 17,989.0 /  9,590.1
  • Price / Sales
  • Price / Book 15.95
  • Forward Div Yield 1.11%
  • Trailing Div Yield

Morningstar‘s Stock Analysis LIXT

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics LIXT

Company Profile LIXT

Business Description

Lixte Biotech Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.

680 East Colorado Boulevard, Suite 180
Pasadena, CA, 91101
Industry Biotechnology
Employees 4

Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.

Lixte Biotech Holdings Inc


Aravive Inc


AnaptysBio Inc


INmune Bio Inc

−$0.58 (9.42%) −$0.17 (9.60%) −$0.03 (0.16%) −$0.13 (1.55%)
Market Cap
9.27 Mil95.75 Mil496.11 Mil148.05 Mil
Biotechnology Biotechnology Biotechnology Biotechnology

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Lixte Biotech Holdings Inc Stock

No. LIXT does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

LIXT’s market cap is 9.27 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

LIXT’s stock style is Small Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

LIXT’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare LIXT’s historical performance against its industry peers and the overall market.